In November, Amylin announced a $1 billion partnership with Osaka, Japan–based Takeda to codevelop and commercialize obesity treatments. Takeda paid the San Diego–based biotech $75 million ...
The Gubra drug a peptide engineered to be an analog for amylin, a hormone that helps regulate blood sugar and food intake. It is specifically designed to bind to and activate amylin and calcitonin ...
In addition, there will be a $350 million up-front payment as Abbvie takes over the reins of GUB-014295 (referred to as Gubamy), a long-acting analog of the satiety hormone amylin, currently in phase ...
AbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of Obesity
Agreement will enable the incorporation of GUB014295, an amylin peptide discovered and developed by Gubra, into AbbVie's global infrastructure for developing and commercializing therapies for ...
AbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of Obesity
GUB014295 is currently in a Phase 1 clinical trial. A potential long-acting amylin analog, GUB014295 is an agonist that specifically activates amylin and calcitonin receptors. Amylin, a satiety ...
GUB014295 is currently in a phase 1 clinical trial. A potential long-acting amylin analog, GUB014295 is an agonist that specifically activates amylin and calcitonin receptors. Amylin, a satiety ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback